MRD - Head of Solid Tumor Diagnostics, Top 10 Pharma

A solid tumor diagnostics lead at a multinational pharmaceutical company discusses theiropinions around MRD and monitoring across different cancer indications, with their optimism forthese technologies focused on CRC. This stakeholder works at a company that conducts ctDNAtesting across thousands of patients in clinical trials every year, and is familiar with the MRDofferings from vendors such as Foundation Medicine, Natera, Guardant, Personalis,NeoGenomics, Invitae, Inivita, and Grail. This stakeholder dives deeply into the pain pointsaround sequencing tumors, outlines future trends around using WGS and methylationsequencing, and expresses a sentiment that the MRD/monitoring market will eventually bedominated by 1-2 key players.

‍